Diplomat
Diplomat

Diplomat Pharmacy, under Pressure, Merges with OptumRx

In early November, Diplomat Pharmacy, Inc. (NYSE: DPLO) revealed some troubling news. The company reported a net loss of $177.3 million in its third-quarter earnings report, its third in a row, and issued a “going concern” warning. Shares dropped 50% (from $6.20 to $3.10) that morning. Brian Griffin, chairman and CEO of Diplomat, cited industry […]

Avella Specialty Pharmacy Goes to OptumRx

The auction for Riordan, Lewis & Haden‘s portfolio company, Avella Specialty Pharmacy, was well under way back in February, according to industry sources. UnitedHealth Group‘s (NYSE: UNH) Optum was reported to be in the lead, and then things went dark. It wasn’t until UnitedHealth Group’s third quarter earnings report was published on October 16 that […]

Personalized Medicine Isn’t All Biotech

There are many sides to personalized medicine, and genetic testing is just one. Another cropped up last week in an acquisition made by Restore Health, a privately held Wisconsin company that provides personalized medicines to health care providers across the United States. Its target was Diplomat Pharmacy’s (NYSE: DPLO) compounding pharmacy business, which includes preparation […]